Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Rheumatoid factor-negative polyarthritis is a term used to describe a group of poorly defined heterogenous conditions that incorporates forms of rheumatoid factor-negative polyarthritis and forms of oligoarticular arthritis that become extensive in less than 6 months after onset.
Biomarker and diagnostic research for rheumatoid factor-negative juvenile idiopathic arthritis has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
No clinical trials have been registered for rheumatoid factor-negative juvenile idiopathic arthritis.
153 publications have been identified in PubMed for rheumatoid factor-negative juvenile idiopathic arthritis. Research spans Basic Science / Preclinical (27%), Review / Meta-Analysis (26%), and Epidemiology / Natural History (20%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 41 | 27% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 3:22 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
40 |
26% |
Disease patterns and progression | 30 | 20% |
Testing and diagnosis research | 20 | 13% |
Clinical study results | 18 | 12% |
Patient case studies | 2 | 1% |
New treatment approaches | 2 | 1% |
Qureshi S (2026). [PMID: 41672721](https://pubmed.ncbi.nlm.nih.gov/41672721/). *RMD Open*. [Review / Meta-Analysis]
Suzuki K (2026). [PMID: 42154323](https://pubmed.ncbi.nlm.nih.gov/42154323/). *Rheumatol Int*. [Review / Meta-Analysis]
Belančić A (2026). [PMID: 42104651](https://pubmed.ncbi.nlm.nih.gov/42104651/). *Croat Med J*. [Review / Meta-Analysis]
Li Y (2026). [PMID: 41574607](https://pubmed.ncbi.nlm.nih.gov/41574607/). *JCI Insight*. [Basic Science / Preclinical]
Kumar A (2026). [PMID: 41359097](https://pubmed.ncbi.nlm.nih.gov/41359097/). *Inflammopharmacology*. [Review / Meta-Analysis]
Mahini SM (2026). [PMID: 41483844](https://pubmed.ncbi.nlm.nih.gov/41483844/). *Clinica chimica acta; international journal of clinical chemistry*. [Review / Meta-Analysis]
Smolen JS (2026). [PMID: 41617358](https://pubmed.ncbi.nlm.nih.gov/41617358/). *RMD open*. [Clinical Trial Publication]
Janssen LMF (2026). [PMID: 41656295](https://pubmed.ncbi.nlm.nih.gov/41656295/). *Part Fibre Toxicol*. [Epidemiology / Natural History]
Zhang X (2026). [PMID: 41729125](https://pubmed.ncbi.nlm.nih.gov/41729125/). *Ann Med*. [Diagnostic / Biomarker]
Bonilla M (2026). [PMID: 40512337](https://pubmed.ncbi.nlm.nih.gov/40512337/). *Odontology*. [Diagnostic / Biomarker]